Question explored with the scientific record
How large is the absolute risk reduction from the Pfizer BNT162b2 vaccine in the original trial?
The short version: the original Pfizer trial's absolute risk reduction was never in the retrieved evidence, so I cannot give you that number.
The records retrieved for this question cover GLP-1 receptor agonists, statins, physical activity, colon cancer chemotherapy, knee surgery, air pollution, and hernia repair [1][2][3][4][5][6][7][8][9][10][11][12]. None of them report the Pfizer BNT162b2 trial, its case counts, or its absolute risk reduction. That is a fact about this search, not about the world.
What I can tell you from general knowledge, clearly outside these records: the original trial reported roughly 95% relative efficacy against symptomatic COVID-19, which translated to an absolute risk reduction of well under 1 percentage point over a few months because the placebo infection rate was low. But I have no retrieved record backing those figures, so treat them as background, not as evidence.
The question you asked is answerable from the trial's published results, but this retrieval did not surface them. A search specifically for the Pfizer phase 3 trial's primary efficacy analysis would settle it.
My call: the evidence retrieved does not contain the Pfizer trial's absolute risk reduction, so I cannot state it as grounded fact. Confidence: not clear.
Sources used 12
-
Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods
This study integrates individual-level data from two GLP-1RA cardiovascular outcome trials with a large Italian real-world diabetes population to show that trial benefits generalize to routine care and to identify older adults without prior cardiovascular disease who gain substa…
DOI: 10.1186/s12933-025-02952-w -
Physical Activity and Mortality across Cardiovascular Disease Risk Groups
A large, nationally representative cohort study using the Health and Retirement Study to assess whether the mortality benefits of physical activity differ across cardiovascular disease (CVD) risk groups; findings show similar relative benefits across risk groups but greater abso…
DOI: 10.1249/01.MSS.0000145443.02568.7A -
Do statins reduce mortality in older people? Findings from a longitudinal study using primary care records
A large retrospective cohort study using The Health Improvement Network primary care records in England and Wales finds that current statin prescription is associated with significant reductions in all-cause mortality from age 65 onwards among adults aged 60+, with greater absol…
DOI: 10.1136/fmch-2020-000780 -
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer?
This Lancet debate argues that adjuvant fluorouracil-based chemotherapy for stage II colon cancer may provide a small relapse-free/overall survival benefit but requires careful patient selection and further large, well-designed trials.
DOI: 10.1016/s1470-2045(06)70727-6 -
National evidence linking robotic total knee arthroplasty to reduced 90-day readmissions, complications, and readmission costs
Robotic-assisted total knee arthroplasty is linked to fewer 90-day readmissions, reduced postoperative complications, and lower readmission costs compared with conventional TKA in a large national cohort.
DOI: 10.1186/s42836-026-00373-y -
Statin Use is Associated with a Less Severe Disease Course In Inflammatory Bowel Disease: A Nationwide Cohort Study 2006-2020
Using Swedish nationwide health registers, this study evaluated whether statin use after inflammatory bowel disease (IBD) diagnosis is associated with a reduced risk of IBD-related surgery, hospitalizations, and disease flares, finding notable reductions in ulcerative colitis an…
DOI: 10.1093/ibd/izaf077 -
Contemporary Use and Outcomes of Arterial Closure Devices After Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program
This VA-based study analyzes the contemporary use and outcomes of arterial closure devices (ACDs) after femoral-approach percutaneous coronary intervention, showing a propensity-matched reduction in major bleeding but no difference when using an operator-based instrumental varia…
DOI: 10.1161/JAHA.119.015223 -
Treatment of stage I seminoma: is it time to change your practice?
An editorial evaluating updated results of the large MRC randomized trial comparing a single course of carboplatin with adjuvant radiotherapy for stage I seminoma, arguing that although carboplatin shows favorable short-term toxicity and convenience, the trial did not definitive…
DOI: 10.1186/1756-8722-1-22 -
Novel approaches to treat portal hypertension
This narrative review synthesizes evidence on pharmacological, endoscopic, and shunt treatments for portal hypertension, emphasizing that non-selective beta-blockers reduce first variceal bleeding and that hemodynamic targets (HVPG <12 mmHg or ≥20% reduction) predict favorable o…
DOI: 10.1046/j.1440-1746.17.s3.6.x -
Laparoscopic hernia repair in children: does recreating the open operation improve outcomes? A systematic review
This systematic review and meta-analysis compares two laparoscopic techniques for pediatric inguinal hernia repair—laparoscopic sac dissection with suturing (LSDS) versus laparoscopic suture ligation (LS)—finding that recreating the open sac dissection significantly reduces recu…
DOI: 10.1007/s10029-023-02772-5 -
Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials
This meta-analysis investigates the efficacy of β-blockers in reducing mortality among patients with chronic heart failure (CHF) and diabetes mellitus, finding that while these patients benefit from β-blocker therapy, the magnitude of the benefit is less than that observed in no…
DOI: 10.1016/S0002-8703(03)00403-4 -
Assessment of health economic losses caused by PM2.5 and ozone pollution in Beijing and Tianjin
An ecological assessment quantifying the health economic losses from PM2.5 and ozone pollution in Beijing and Tianjin from 2016–2021 by combining Poisson-regression based health impact assessment with value-of-statistical-life monetization and hospitalization cost methods, revea…
DOI: 10.1038/s41598-025-03143-z